Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

Brookstone Capital Management trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.9% in the fourth ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

A report on the experiences of 13 patients found that the drug had no benefit for some and that some who benefited said the ...

Pfizer (NYSE:PFE – Get Free Report) had its price objective lowered by analysts at UBS Group from $31.00 to $29.00 in a ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long ...

A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid ...

Pfizer's stock has plummeted due to declining ... However, in 2024 COVID-19 products together (Comirnaty and anti-viral Paxlovid) are expected to contribute only 16-17% to total sales (about ...

Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death Final data available ...

The Biden administration’s bird flu response has been too slow. Now comes a test for Trump’s White House.

Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi ...